Literature DB >> 20043919

The humanness of macaque antibody sequences.

Philippe Thullier1, Oliver Huish, Thibaut Pelat, Andrew C R Martin.   

Abstract

Chimeric, humanized and human antibodies have successively been exploited as therapeutics because their increasing human ('self') character is expected to correspond with decreased immunogenicity, which is critical for their clinical development. Thus, humanness has been inferred to predict antibody immunogenicity. Humanness of antibody variable regions (V-regions) has recently been studied using a parameter (here referred to as the H-score) that evaluates similarity to expressed human sequences. Macaque (Macaca fascicularis) antibody sequences are of particular interest because they have been suggested to have extremely human-like character and, recently, macaque single-chain variable fragments with very high affinity for various antigens have been isolated. In this study, the H-scores of all macaque antibody V-regions available in sequence data banks were compared with those of their human counterparts using statistical tests. The results were found to be influenced by the relative size of the human families to which the macaque V-regions are related. As the relevance of families to immunogenicity is suspected but unproven, a new parameter (the 'G-score') was derived from the H-score to avoid this influence, and macaque V-region sequences were reanalyzed using the G-score. Both parameters show that these regions cannot be regarded as human when they derive from heavy chains, but the humanness of light chains is variable. It was shown that 'germline humanization' of a macaque V-region favourably influenced its humanness, as evaluated by both H-score and G-score. In addition, the humanness of macaque sequences presented in patents has been analyzed. The H-score and G-score define objectively the humanness of antibody V-regions, and their use is exemplified here. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043919     DOI: 10.1016/j.jmb.2009.12.041

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  18 in total

1.  Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins.

Authors:  Benoît-Joseph Laventie; Hendrik Jan Rademaker; Maher Saleh; Ernie de Boer; Rick Janssens; Tristan Bourcier; Audrey Subilia; Luc Marcellin; Rien van Haperen; Joyce H G Lebbink; Tao Chen; Gilles Prévost; Frank Grosveld; Dubravka Drabek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering.

Authors:  Philippe Thullier; Siham Chahboun; Thibaut Pelat
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

3.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

4.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

Review 5.  Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.

Authors:  Rahul Khetan; Robin Curtis; Charlotte M Deane; Johannes Thorling Hadsund; Uddipan Kar; Konrad Krawczyk; Daisuke Kuroda; Sarah A Robinson; Pietro Sormanni; Kouhei Tsumoto; Jim Warwicker; Andrew C R Martin
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

Review 6.  Computer-aided antibody design.

Authors:  Daisuke Kuroda; Hiroki Shirai; Matthew P Jacobson; Haruki Nakamura
Journal:  Protein Eng Des Sel       Date:  2012-06-02       Impact factor: 1.650

7.  Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin.

Authors:  Siham Chahboun; Michael Hust; Yvonne Liu; Thibaut Pelat; Sebastian Miethe; Saskia Helmsing; Russell Ga Jones; Dorothea Sesardic; Philippe Thullier
Journal:  BMC Biotechnol       Date:  2011-11-23       Impact factor: 2.563

8.  Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Authors:  Torsten Rülker; Luzie Voß; Philippe Thullier; Lyn M O' Brien; Thibaut Pelat; Stuart D Perkins; Claudia Langermann; Thomas Schirrmann; Stefan Dübel; Hans-Jürgen Marschall; Michael Hust; Birgit Hülseweh
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

9.  Humanization and characterization of an anti-ricin neutralization monoclonal antibody.

Authors:  Wei-Gang Hu; Junfei Yin; Damon Chau; Laurel M Negrych; John W Cherwonogrodzky
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

10.  Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.

Authors:  Sebastian Miethe; Christine Rasetti-Escargueil; Arnaud Avril; Yvonne Liu; Siham Chahboun; Hannu Korkeala; Christelle Mazuet; Michel-Robert Popoff; Thibaut Pelat; Philippe Thullier; Dorothea Sesardic; Michael Hust
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.